Email updates

Keep up to date with the latest news and content from Journal of Hematology & Oncology and BioMed Central.

Open Access Highly Accessed Review

Angiogenesis inhibitors in the treatment of prostate cancer

Clara Hwang1* and Elisabeth I Heath2

Author Affiliations

1 Department of Internal Medicine, Henry Ford Hospital, CFP 559, 2799 West Grand Blvd, Detroit, MI 48202, USA

2 Karmanos Cancer Institute and Wayne State University School of Medicine, 4234 KCI, 4100 John R, Detroit, MI, 48201, USA

For all author emails, please log on.

Journal of Hematology & Oncology 2010, 3:26  doi:10.1186/1756-8722-3-26

Published: 2 August 2010

Abstract

Prostate cancer remains a significant public health problem, with limited therapeutic options in the setting of castrate-resistant metastatic disease. Angiogenesis inhibition is a relatively novel antineoplastic approach, which targets the reliance of tumor growth on the formation of new blood vessels. This strategy has been used successfully in other solid tumor types, with the FDA approval of anti-angiogenic agents in breast, lung, colon, brain, and kidney cancer. The application of anti-angiogenic therapy to prostate cancer is reviewed in this article, with attention to efficacy and toxicity results from several classes of anti-angiogenic agents. Ultimately, the fate of anti-angiogenic agents in prostate cancer rests on the eagerly anticipated results of several key phase III studies.